Press release
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, Consumer Demand and Key Opportunities
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the arms and legs due to damage to the myelin sheath surrounding peripheral nerves. Though uncommon, CIDP significantly affects patient quality of life and requires long-term management, often involving immunotherapy, corticosteroids, and plasma exchange.
Over the past decade, improved diagnostic capabilities, greater awareness of rare neurological diseases, and advancements in immunoglobulin therapies have fueled growth in the CIDP treatment market. With an expanding patient base, the increasing adoption of innovative biologics, and the rising demand for home-based infusion therapies, the market is poised for steady growth through 2034.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71900
Market Overview
The global chronic inflammatory demyelinating polyneuropathy (CIDP) market was valued at USD 3.2 billion in 2024 and is projected to grow at a CAGR of 7.4% between 2024 and 2034, reaching approximately USD 6.6 billion by 2034.
Key Highlights
• Drivers: Rising prevalence of autoimmune disorders, increased adoption of intravenous immunoglobulin (IVIg) therapy, and advancements in plasma exchange and corticosteroid treatments.
• Challenges: High cost of immunoglobulin therapies, limited awareness in low-income regions, and the risk of relapse requiring lifelong management.
• Leading Players: CSL Behring, Grifols S.A., Octapharma AG, Takeda Pharmaceutical, Kedrion Biopharma, Pfizer Inc., Bayer AG, Sanofi, Biotest AG, and Baxter International.
Segmentation Analysis
By Product
• Intravenous Immunoglobulin (IVIg)
• Subcutaneous Immunoglobulin (SCIg)
• Corticosteroids
• Plasma Exchange (Plasmapheresis)
• Immunosuppressants
• Emerging Biologics & Monoclonal Antibodies
By Platform
• Hospital-Based Therapies
• Home-Based Infusion Therapies
By Technology
• Conventional Immunotherapy
• Advanced Immunoglobulin Delivery Systems
• Monoclonal Antibody Innovations
By End Use
• Hospitals
• Specialty Neurology Clinics
• Ambulatory Care Centers
• Homecare Settings
By Application
• Adult Patients
• Pediatric Patients
Segmentation Summary
Intravenous immunoglobulin (IVIg) therapy remains the gold standard for CIDP management, accounting for the majority of market revenue. However, subcutaneous immunoglobulin (SCIg) is rapidly gaining traction due to ease of administration and patient preference for homecare settings. Biologics and monoclonal antibodies under development promise to expand future treatment options.
Regional Analysis
North America
• Largest market share driven by advanced healthcare infrastructure, high diagnosis rates, and strong adoption of IVIg therapies.
• The U.S. dominates due to favorable reimbursement policies and growing clinical research activities.
Europe
• Strong demand supported by well-established rare disease management programs and wide availability of plasma therapies.
• Germany, France, and the U.K. lead with robust adoption of IVIg and SCIg treatments.
Asia-Pacific
• Fastest-growing region, fueled by rising awareness of rare diseases, increasing healthcare investments, and expanding access to advanced immunotherapies.
• China, Japan, and India are major growth contributors.
Middle East & Africa
• Gradual expansion due to increasing awareness and growing access to plasma therapies.
• Limited affordability and infrastructure remain barriers, though GCC countries are seeing improved uptake.
Latin America
• Brazil and Mexico are leading regional markets, with increased investment in neurology and rare disease care.
Regional Summary
North America and Europe dominate revenues today, but Asia-Pacific is projected to achieve the highest CAGR due to an expanding patient pool, rapid healthcare modernization, and improved diagnostic infrastructure.
Market Dynamics
Key Growth Drivers
• Increasing prevalence of autoimmune and neurological disorders globally.
• Growing adoption of IVIg and SCIg therapies.
• Rising healthcare spending on rare disease management.
• Expanding clinical trials pipeline for biologics and monoclonal antibodies.
Key Challenges
• High cost of immunoglobulin and biologic therapies.
• Relapse risks requiring ongoing and lifelong treatment.
• Limited awareness and underdiagnosis in emerging markets.
Latest Trends
• Expansion of home-based infusion therapies for patient convenience.
• Development of long-acting immunoglobulin formulations.
• Clinical trials for monoclonal antibodies and next-generation biologics targeting CIDP.
• Increased partnerships between plasma therapy companies and healthcare providers.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71900/cognitive-impairment-associated-with-schizophrenia-market
Competitor Analysis
Major Players
• CSL Behring - Market leader in immunoglobulin therapies for rare diseases.
• Grifols S.A. - Strong plasma therapy portfolio.
• Octapharma AG - Specialized in immunotherapy and neurology-focused products.
• Takeda Pharmaceutical - Wide portfolio in rare diseases and immunology.
• Kedrion Biopharma - Focused on plasma-derived therapies.
• Pfizer Inc. - Expanding into neurology and biologic treatments.
• Bayer AG - Active in R&D for autoimmune disease therapies.
• Sanofi - Strong pipeline of biologics for rare diseases.
• Biotest AG - Specialist in plasma proteins and immunotherapy.
• Baxter International - Innovator in infusion and plasma therapies.
Competitive Landscape Summary
The CIDP market is moderately consolidated, with plasma therapy giants dominating IVIg and SCIg treatments, while pharmaceutical leaders focus on biologics and R&D pipelines. Strategic alliances, product launches, and expansion into emerging markets are key strategies shaping competition.
Conclusion
The chronic inflammatory demyelinating polyneuropathy (CIDP) market is poised for robust growth over the next decade. Rising prevalence, improved diagnostic capabilities, and the increasing adoption of IVIg and SCIg therapies are driving expansion. While high costs and limited awareness remain obstacles, advancements in biologics and home-based care create strong opportunities.
By 2034, the market is expected to reach USD 6.6 billion, underscoring steady demand for immunoglobulin therapies and novel treatment approaches. Companies focusing on innovation, affordability, and patient-centric delivery methods will be best positioned to capture market growth.
For stakeholders, the CIDP market represents a rare disease opportunity with significant potential to improve patient outcomes and expand access to life-changing therapies worldwide.
This report is also available in the following languages : Japanese (統合失調症に伴う認知障害市場), Korean (정신분열증과 관련된 인지 장애 시장), Chinese (精神分裂症相关认知障碍市场), French (Déficience cognitive associée à la schizophrénie), German (Markt für kognitive Beeinträchtigungen im Zusammenhang mit Schizophrenie), and Italian (Deficit cognitivo associato al mercato della schizofrenia), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71900
Our More Reports:
Atypical Teratoid Rhabdoid Tumors Market
https://exactitudeconsultancy.com/reports/71926/atypical-teratoid-rhabdoid-tumors-market
Chronic Progressive Multiple Sclerosis Market
https://exactitudeconsultancy.com/reports/71928/chronic-progressive-multiple-sclerosis-market
Clinically Isolated Syndrome (CIS) Market
https://exactitudeconsultancy.com/reports/71930/clinically-isolated-syndrome-cis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, Consumer Demand and Key Opportunities here
News-ID: 4179642 • Views: …
More Releases from Exactitude Consultancy
Vacuum Insulated Pipe Market Projected to Reach USD 2.36 Billion by 2034
Introduction: A Market Built on Cryogenic Efficiency and Innovation
The global Vacuum Insulated Pipe (VIP) market is witnessing a steady surge driven by the expanding cryogenic industry, increased liquefied natural gas (LNG) trade, and rising demand for efficient liquid gas transportation systems. These specialized double-wall pipes, engineered with high vacuum insulation between inner and outer layers, have become indispensable in industries handling cryogenic fluids such as liquid nitrogen, oxygen, argon, and…
Solar PV Mounting Systems Market is Expected to Reach USD 31.7 Billion by 2034
Introduction: Powering the Next Decade of Solar Expansion
The Solar PV Mounting Systems Market is emerging as a crucial pillar in the clean energy revolution, enabling efficient, cost-effective, and durable installations of photovoltaic (PV) modules across rooftops, open fields, and floating structures. As the world accelerates toward carbon neutrality, the demand for robust, modular, and adaptable mounting systems has intensified across residential, commercial, and utility-scale solar projects.
Download Full PDF Sample Copy…
Tall Oil Fatty Acid Market projected to reach USD 2.21 billion by 2034
Introduction: A Sustainable Feedstock Powering the Future of Bio-based Chemicals
The Tall Oil Fatty Acid (TOFA) Market is gaining strong traction as industries increasingly shift toward renewable, sustainable, and bio-based chemical alternatives. Derived as a byproduct from the kraft pulping process of pine wood, TOFA has become a vital raw material in the production of alkyd resins, dimer acids, lubricants, coatings, and adhesives. Its unique composition-rich in oleic and linoleic acids-makes…
Lithium-Ion Battery Recycling Market Projected to Reach USD 27.3 Billion by 2034
Introduction: Powering the Circular Energy Transition
As the world accelerates toward electrification and clean energy, the demand for lithium-ion batteries has skyrocketed-fueling everything from electric vehicles (EVs) to smartphones and grid storage systems. However, this exponential growth brings with it an urgent environmental challenge: how to sustainably manage end-of-life batteries.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/25354
The Lithium-Ion Battery Recycling Market has emerged as a cornerstone of the global…
More Releases for CIDP
CIDP Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landsca …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Inflammatory Demyelinating Polyneuropathy pipeline constitutes 2+ key companies continuously working towards developing 4+ Chronic Inflammatory Demyelinating Polyneuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
CIDP Market Emerging Trends and Growth Prospects 2034
Introduction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neuropathy characterized by progressive or relapsing weakness, sensory loss, and impaired reflexes due to demyelination of peripheral nerves. Unlike acute Guillain-Barré syndrome, CIDP evolves over at least eight weeks and, without timely treatment, can lead to significant long-term disability. The condition encompasses typical CIDP and several clinical variants (e.g., MADSAM/Lewis-Sumner, DADS, pure motor, pure sensory), each with nuanced diagnostic and therapeutic…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Forayi …
Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder which causes paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an immunosuppressant, plasma…
